Hemolytic uremic syndrome after pediatric liver transplantation

Journal of Pediatric Gastroenterology and Nutrition

Volumn 43, Issue 1, 2006, Pages 109-112

  Turner, Dan ^a   Schreiber, Ruth ^a   Grant, David ^a   Hebert, Diane ^a   Sherman, Philip M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMLODIPINE; AMPICILLIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCINEURIN INHIBITOR; CEFOTAXIME; CREATININE; CYTOMEGALOVIRUS ANTIBODY; FLUCONAZOLE; GAMMA GLUTAMYLTRANSFERASE; GANCICLOVIR; GENTAMICIN; HAPTOGLOBIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LABETALOL; LACTATE DEHYDROGENASE; MEROPENEM; METHYLPREDNISOLONE; METRONIDAZOLE; NIFEDIPINE; OCTREOTIDE; OKT 3; PANTOPRAZOLE; PROPRANOLOL; RAPAMYCIN; SHIGA TOXIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE KIDNEY FAILURE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BILIARY CIRRHOSIS; BILIRUBIN BLOOD LEVEL; BLOOD SMEAR; CANDIDA ALBICANS; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DOPPLER ECHOGRAPHY; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI; ESOPHAGUS VARICES; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LAPAROTOMY; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; PLASMAPHERESIS; PORTAL HYPERTENSION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SCHOOL CHILD; SEPSIS; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREMIA; URINARY TRACT INFECTION; URINE VOLUME;

CHILD; CHOLANGITIS, SCLEROSING; ESCHERICHIA COLI INFECTIONS; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TACROLIMUS;

EID: 33745775011     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000189364.14664.90     Document Type: Article

References (22)

1. Tarr PI, Gordon CA, Chandler WL. Shiga toxin producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365:1073-86.
2. Siegler R, Oakes R. Hemolytic uremic syndrome: pathogenesis, treatment, and outcome. Curr Opin Pediatr 2005;17:200-4.
3. Leithner C, Sinzinger H, Pohanka E, et al. Recurrence of haemolytic uraemic syndrome triggered by cyclosporin A after renal transplantation. Lancet 1982;319:1470.
4. Lin CC, King KL, Chao YW, et al. Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol 2003;16:580-5.
5. Trimarchi HM, Truong LD, Brennan S, et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation 1999;67:539-44.
6. Holman MJ, Gonwa TA, Cooper B, et al. FK506-associated thrombotic thrombocytopenic purpura. Transplantation 1993;55:205-6.
7. Mach-Pascual S, Samii K, Beris P. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. Am J Hematol 1996;52:310-2.
8. Rerolle JP, Akposso K, Lerolle N, et al. Tacrolimus-induced hemolytic uremic syndrome and end-stage renal failure after liver transplantation. Clin Transplant 2000;14:262-5.
9. Singh N, Gayowski T, Marino IR. Hemolytic uremic syndrome in solid-organ transplant recipients. Transpl Int 1996;9:68-75.
10. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001;8:286-93.
11. Remuzzi G, Bertani T. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989;13:261-72.
12. Banerjee D, Kupin W, Roth D. Hemolytic uremic syndrome after multivisceral transplantation treated with intravenous immunoglobulin. J Nephrol 2003;16:733-5.
13. Brown Z, Neild GH. FK-506 and haemolytic uremic syndrome. Lancet 1990;335:412.
14. Remuzzi G, Misiani R, Marchesi D, et al. Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet 1978;312:871-2.
15. Moutabarrik A, Ishibashi M, Fukunaga M, et al. FK506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells. Transpl Int 1992;1 (5 Suppl):S93-7.
16. McCauley J, Bronsther O, Fung J, et al. Treatment of cyclosporine-induced haemolytic uraemic syndrome with FK506. Lancet 1989;334:1516.
17. Tanabe K, Tokumoto T, Ishida H, et al. Prospective analysis of thrombotic microangiopathy after renal transplantation: comparison between cyclosporine and tacrolimus immunosuppression. Transplant Proc 2002;34:1819-20.
18. Grupp C, Schmidt F, Braun F, et al. Haemolytic uraemic syndrome (HUS) during treatment with cyclosporin A after renal transplantation: is tacrolimus the answer? Nephrol Dial Transplant 1998;13:1629-31.
19. Bradford-Hill A. Principles of Medical Statistics, 9th ed. New York: Oxford University Press, 1971, 309-23.
20. Ramasubbu K, Mullick T, Koo A, et al. Thrombotic microangiopathy and cytomegalovirus in liver transplant recipients: a case-based review. Transpl Infect Dis 2003;5:98-103.
21. Von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 2002;6:320-8.
22. Franco A, Hernandez D, Capdevilla L, et al. De-novo hemolytic uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus. Transplant Proc 2003;35:1764-6.